Latest Insider Transactions at Catalent, Inc. (CTLT)
This section provides a real-time view of insider transactions for Catalent, Inc. (CTLT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Catalent, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Catalent, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 27
2023
|
Rosemary A Crane Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+22.66%
|
-
|
|
Oct 27
2023
|
Rolf A Classon Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+13.9%
|
-
|
|
Oct 27
2023
|
Frank A Damelio Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+46.73%
|
-
|
|
Oct 27
2023
|
Gregory T Lucier Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+17.82%
|
-
|
|
Oct 27
2023
|
Christa Kreuzburg Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,245
-6.21%
|
$48,555
$39.32 P/Share
|
|
Oct 27
2023
|
Christa Kreuzburg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+25.86%
|
-
|
|
Oct 27
2023
|
Jack L Stahl Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+13.9%
|
-
|
|
Oct 27
2023
|
Donald E Morel Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+9.65%
|
-
|
|
Oct 27
2023
|
Michelle R Ryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+43.8%
|
-
|
|
Oct 27
2023
|
Stephanie Okey Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,993
+46.73%
|
-
|
|
Oct 17
2023
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
BUY
Grant, award, or other acquisition
|
Direct |
2,708
+25.64%
|
-
|
|
Oct 16
2023
|
Patricia Hunt Pres. Consumer Health Div |
SELL
Payment of exercise price or tax liability
|
Direct |
22
-0.19%
|
$1,012
$46.52 P/Share
|
|
Sep 10
2023
|
Steven Barg Director |
BUY
Grant, award, or other acquisition
|
Direct |
718
+50.0%
|
-
|
|
Aug 31
2023
|
Michelle R Ryan Director |
BUY
Open market or private purchase
|
Direct |
1,000
+33.57%
|
$49,000
$49.98 P/Share
|
|
Aug 30
2023
|
John J Greisch Executive Chair |
BUY
Open market or private purchase
|
Indirect |
21,000
+38.18%
|
$1,050,000
$50.24 P/Share
|
|
Aug 28
2023
|
Stephanie Okey Director |
BUY
Grant, award, or other acquisition
|
Direct |
979
+50.0%
|
-
|
|
Aug 28
2023
|
Michelle R Ryan Director |
BUY
Grant, award, or other acquisition
|
Direct |
979
+50.0%
|
-
|
|
Aug 28
2023
|
Frank A Damelio Director |
BUY
Grant, award, or other acquisition
|
Direct |
979
+50.0%
|
-
|
|
Aug 24
2023
|
Steven L Fasman EVP & Chief Admin Officer |
SELL
Open market or private sale
|
Direct |
817
-1.1%
|
$35,948
$44.65 P/Share
|
|
Aug 24
2023
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
SELL
Open market or private sale
|
Direct |
396
-0.41%
|
$17,424
$44.49 P/Share
|
|
Aug 24
2023
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
SELL
Open market or private sale
|
Direct |
390
-1.57%
|
$17,160
$44.5 P/Share
|
|
Aug 24
2023
|
Scott Gunther SVP, Quality & Reg. Affairs |
SELL
Open market or private sale
|
Direct |
269
-0.89%
|
$11,836
$44.57 P/Share
|
|
Aug 24
2023
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
2,071
-1.15%
|
$91,124
$44.83 P/Share
|
|
Aug 24
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
SELL
Open market or private sale
|
Direct |
276
-1.24%
|
$12,144
$44.56 P/Share
|
|
Aug 24
2023
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
SELL
Open market or private sale
|
Direct |
87
-0.15%
|
$3,828
$44.87 P/Share
|
|
Aug 24
2023
|
Lorenzo Carletti SVP Global Ops Ph & Cons Hlth |
SELL
Open market or private sale
|
Direct |
216
-2.41%
|
$9,504
$44.71 P/Share
|
|
Aug 24
2023
|
Charles Lickfold SVP, CIO |
SELL
Open market or private sale
|
Direct |
190
-1.65%
|
$8,360
$44.72 P/Share
|
|
Aug 24
2023
|
Thomas W Hawkeswood Pres. Pharma Prod Delivery Div |
SELL
Open market or private sale
|
Direct |
147
-1.91%
|
$6,468
$44.72 P/Share
|
|
Aug 24
2023
|
Patricia Hunt Pres. Consumer Health Div |
SELL
Open market or private sale
|
Direct |
106
-0.93%
|
$4,664
$44.77 P/Share
|
|
Aug 24
2023
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
379
-1.24%
|
$16,676
$44.47 P/Share
|
|
Aug 23
2023
|
Steven L Fasman EVP & Chief Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,226
+2.91%
|
-
|
|
Aug 23
2023
|
Aristippos Gennadios Group Pres. Pharma & Consumer |
BUY
Grant, award, or other acquisition
|
Direct |
1,590
+1.61%
|
-
|
|
Aug 23
2023
|
Michael J Grippo SVP, Strategy & Corp. Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
1,114
+4.29%
|
-
|
|
Aug 23
2023
|
Scott Gunther SVP, Quality & Reg. Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
1,081
+3.46%
|
-
|
|
Aug 23
2023
|
Alessandro Maselli President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,974
+4.23%
|
-
|
|
Aug 23
2023
|
Ricky Hopson Pres. BioProduct Delivery, CoS |
BUY
Grant, award, or other acquisition
|
Direct |
789
+3.49%
|
-
|
|
Aug 23
2023
|
Jonathan Arnold SVP, CCO & Div. Head BioP Del. |
BUY
Grant, award, or other acquisition
|
Direct |
1,590
+2.69%
|
-
|
|
Aug 23
2023
|
Lorenzo Carletti SVP Global Ops Ph & Cons Hlth |
BUY
Grant, award, or other acquisition
|
Direct |
457
+4.85%
|
-
|
|
Aug 23
2023
|
Charles Lickfold SVP, CIO |
BUY
Grant, award, or other acquisition
|
Direct |
637
+5.24%
|
-
|
|
Aug 23
2023
|
Thomas W Hawkeswood Pres. Pharma Prod Delivery Div |
BUY
Grant, award, or other acquisition
|
Direct |
268
+3.37%
|
-
|
|
Aug 23
2023
|
Patricia Hunt Pres. Consumer Health Div |
BUY
Grant, award, or other acquisition
|
Direct |
289
+2.47%
|
-
|
|
Aug 23
2023
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,081
+3.41%
|
-
|
|
Aug 01
2023
|
Karen Murphy Santiago VP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,342
+32.96%
|
-
|
|
Aug 01
2023
|
Ricardo Zayas SVP, Operations, Biologics NA |
BUY
Grant, award, or other acquisition
|
Direct |
4,435
+41.61%
|
-
|
|
Aug 01
2023
|
Ricardo Pravda Chief Transformation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,783
+24.89%
|
-
|
|
Aug 01
2023
|
Ricardo Pravda Chief Transformation Officer |
SELL
Open market or private sale
|
Direct |
269
-0.67%
|
$12,643
$47.14 P/Share
|
|
Aug 01
2023
|
Alessandro Maselli President & CEO |
SELL
Open market or private sale
|
Direct |
1,485
-0.85%
|
$69,795
$47.23 P/Share
|
|
Aug 01
2023
|
Charles Lickfold SVP, CIO |
BUY
Grant, award, or other acquisition
|
Direct |
5,322
+32.82%
|
-
|
|
Aug 01
2023
|
Charles Lickfold SVP, CIO |
SELL
Open market or private sale
|
Direct |
135
-2.37%
|
$6,345
$47.9 P/Share
|
|
Aug 01
2023
|
Joseph Anthony Ferraro SVP, General Counsel, CCO |
BUY
Grant, award, or other acquisition
|
Direct |
5,145
+50.0%
|
-
|